Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging. The company sells its products to veterinarians through a field organization and third-party distributors; and trade shows, print advertising, and other distribution relationships. Heska Corporation has product development partnership and licensing agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone970-493-7272
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$127.45 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/3/2019 (Estimated)
OptionableNot Optionable
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Corp (NASDAQ:HSKA) released its quarterly earnings results on Tuesday, February, 26th. The medical research company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.76 by $0.32. Heska had a return on equity of 9.87% and a net margin of 4.59%. View Heska's Earnings History.
When is Heska's next earnings date?
What guidance has Heska issued on next quarter's earnings?
Heska updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $123 million, compared to the consensus revenue estimate of $134.34 million.
What price target have analysts set for HSKA?
4 analysts have issued twelve-month price targets for Heska's stock. Their predictions range from $87.00 to $120.00. On average, they expect Heska's share price to reach $108.3333 in the next twelve months. This suggests a possible upside of 27.0% from the stock's current price. View Analyst Price Targets for Heska.
What is the consensus analysts' recommendation for Heska?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (3/5/2019)
- 2. Canaccord Genuity analysts commented, "We believe the meetings reinforced our long-term thesis on the stock – global expansion, new products, and scarcity value in diagnostics support our BUY thesis. Near term, investors await a 2019 guide on Heska’s earnings call next Tuesday, which we view as a near-term risk event for the stock. We would be more apt to put new money to work after HSKA reports Q4 and sets the bar. Moving up the value chain. We believe most investors do not know or appreciate that HSKA’s livestock/poultry/dairy (LPD) business has value, since growth from that business has been in decline. HSKA plans to manufacture its new immunodiagnostics + and rotor chemistry consumables from Des Moines, IA, leveraging its own USDA- regulated manufacturing facility. Longer term, we think HSKA will get more credit for manufacturing more of its products (accretive to GMs), while today it uses OEMs for most of its revenue." (2/20/2019)
Has Heska been receiving favorable news coverage?
News stories about HSKA stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heska earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Heska's key competitors?
Some companies that are related to Heska include Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT) and Fate Therapeutics (FATE).
What other stocks do shareholders of Heska own?
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)
- Mr. Jason A. Napolitano, COO, Chief Strategist & Sec. (Age 51)
- Ms. Catherine Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)
- Mr. Steven M. Eyl, Exec. VP of Global Sales & Marketing (Age 53)
- Mr. Jon Aagaard, Director of Investor Relations
Who are Heska's major shareholders?
Heska's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.17%), FMR LLC (5.86%), Riverbridge Partners LLC (4.67%), Standard Life Aberdeen plc (3.33%), Ranger Investment Management L.P. (3.03%) and Dimensional Fund Advisors LP (2.89%). Company insiders that own Heska stock include Bonnie J Trowbridge, Carol Wrenn, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Sharon J Larson, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska.
Which institutional investors are selling Heska stock?
HSKA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Raymond James & Associates, Standard Life Aberdeen plc, Riverbridge Partners LLC, Bank of New York Mellon Corp, Barclays PLC, Citigroup Inc. and Bank of America Corp DE. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Steve Asakowicz and Steven M Eyl. View Insider Buying and Selling for Heska.
Which institutional investors are buying Heska stock?
HSKA stock was acquired by a variety of institutional investors in the last quarter, including Ranger Investment Management L.P., AlphaOne Investment Services LLC, Geode Capital Management LLC, Geode Capital Management LLC, Thrivent Financial for Lutherans, Millennium Management LLC, Martingale Asset Management L P and Summit Creek Advisors LLC. View Insider Buying and Selling for Heska.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $85.32.
How big of a company is Heska?
Heska has a market capitalization of $660.55 million and generates $127.45 million in revenue each year. The medical research company earns $5.85 million in net income (profit) each year or $1.42 on an earnings per share basis.
What is Heska's official website?
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (NASDAQ HSKA)
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
